Key result
Leadless LV endocardial pacing improves LVEF by ~6% and NYHA functional class at six months.
Why the study?
Leadless LV endocardial pacing for CRT is a novel procedure for dyssynchronous heart failure, but evidence regarding its safety and efficacy was limited to small observational studies.
Does leadless LV endocardial pacing improve NYHA functional class and LVEF in patients with dyssynchronous heart failure?
Meta-Analysis (n=181)
Does leadless LV endocardial pacing improve NYHA functional class and LVEF in patients with dyssynchronous heart failure?
Effect estimate: MD -0.43 (95% CI -0.76 to -0.1)
p-value: p=.01
Leadless LV endocardial pacing for CRT significantly improves NYHA functional class and LVEF at 6 months, supporting its use as a second-line therapy despite a 23.8% procedure-related complication rate.
No takes yet. Share an insight, caveat, or question.
May support leadless LV endocardial pacing as second-line CRT; extends small-study data but needs RCTs to confirm net benefit.
Wijesuriya et al. (2022) conducted a meta-analysis in dyssynchronous heart failure (n=181). Leadless left ventricular endocardial pacing was evaluated on Mean difference in New York Heart Association (NYHA) functional class from baseline to 6 months postprocedure (MD -0.43, 95% CI -0.76 to -0.1, p=.01). Leadless left ventricular endocardial pacing significantly improved NYHA functional class (MD -0.43; 95% CI -0.76 to -0.1; P=0.01) and LVEF (MD 6.3%; P<0.001) at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: